Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | HTR1D | P28221 | 2/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860394 | 0.89 | RIPK1 (0.72) | RIPK1MAPTSMN1; SMN2TP53GLA | |
| SCHEMBL29764703 | 0.83 | RIPK1 (0.79) | RIPK1MAPTSMN1; SMN2TP53GLA | |
| SCHEMBL877381 | 0.83 | RIPK1 (0.79) | RIPK1MAPTSMN1; SMN2TP53GLA | |
| SCHEMBL876699 | 0.83 | RIPK1 (0.79) | RIPK1MAPTSMN1; SMN2TP53GLA | |
| SCHEMBL837717 | 0.83 | RIPK1 (0.79) | RIPK1MAPTSMN1; SMN2TP53GLA | |
| SCHEMBL17830370 | 0.78 | IDO1 (0.51) | MAPTIDO1HSD17B10L3MBTL1HTR1D | |
| SCHEMBL20053035 | 0.78 | IDO1 (0.51) | MAPTIDO1HSD17B10L3MBTL1HTR1D | |
| SCHEMBL20668166 | 0.78 | HTR1D (0.54) | RIPK1MAPTSMN1; SMN2TP53GLA | |
| SCHEMBL837893 | 0.76 | MAPT (0.71) | RIPK1MAPTSMN1; SMN2TP53GLA | |
| SCHEMBL14235650 | 0.74 | RIPK1 (0.76) | RIPK1MAPTSMN1; SMN2TP53GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023690-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2019-01-24 | — | — | US | disclosed |
| US-9944628-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944628-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-17 | — | — | US | disclosed |
| US-9499521-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499521-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-16 | — | — | US | disclosed |
| WO-2016094846-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | RIPK1 198/4885MAPT 94/4885SMN1; SMN2 665/4885 |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | RIPK1 198/4885MAPT 94/4885SMN1; SMN2 665/4885 |
| US-20190023690-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | RIPK1 198/4885MAPT 94/4885SMN1; SMN2 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.